Natural Products for Type II Diabetes Treatment

Advances in Applied Microbiology

Volumn 71, Issue , 2010, Pages 21-73

  Bedekar, Amruta ^a   Shah, Karan ^a   Koffas, Mattheos ^a  

^a UNIVERSITY AT BUFFALO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; BIOLOGICAL PRODUCT; ENZYME INHIBITOR; PLANT EXTRACT;

BACTERIUM; BARK; CHEMISTRY; HUMAN; METABOLISM; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; PHYTOTHERAPY; PINE; RANDOMIZED CONTROLLED TRIAL; REVIEW;

BACTERIA; BIOLOGICAL PRODUCTS; DIABETES MELLITUS, TYPE 2; ENZYME INHIBITORS; HUMANS; HYPOGLYCEMIC AGENTS; MIDDLE AGED; PHYTOTHERAPY; PINUS; PLANT BARK; PLANT EXTRACTS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 77952294747     PISSN: 00652164     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S0065-2164(10)71002-9     Document Type: Chapter

References (172)

1. Abe, M., et al. Combination therapy of pioglitazone with voglibose improves glycemic control safely and rapidly in Japanese type 2-diabetic patients on hemodialysis. Clin. Nephrol. 68:5 (2007), 287–294.
2. Ahr, H.J., et al. Pharmacokinetics of acarbose. Part I: Absorption, concentration in plasma, metabolism and excretion after single administration of [14C]acarbose to rats, dogs and man. Arzneimittelforschung 39:10 (1989), 1254–1260.
3. Ahr, H.J., et al. Pharmacokinetics of miglitol. Absorption, distribution, metabolism, and excretion following administration to rats, dogs, and man. Arzneimittelforschung 47:6 (1997), 734–745.
4. Ajabnoor, M.A., et al. Anti-diabetic activity of Teucrium oliverianum. Fitoterapia LV, 2, 1984, 227.
5. Akhtar, M.S., Ali, M.R., Study of hypoglycaemic activity of Cuminum nigrum seeds in normal and alloxan diabetic rabbits. Planta Med. 51:2 (1985), 81–85.
6. Allen, F., Leaf extract: Physiologic and clinical properties in relation to carbohydrate metabolism. JAMA 89 (1927), 1577–1581.
7. Anderson, O.M., Paper presented at the anthocyanin occurrences and analysis., Proceedings of the International Workshop on Anthocyanins: Research and Development of Anthocyanins, Adelaide, South Australia, 2002, 17–19.
8. Anderson, R.A., et al. Isolation and characterization of polyphenol type-A polymers from cinnamon with insulin-like biological activity. J. Agric. Food Chem. 52:1 (2004), 65–70.
9. Apeler, H., et al. Neue Enzyme in der Acarbose-Synthese und deren Verwendung. 2001 German Patent DEOS 10021667.
10. Aslan, M., et al. A study of antidiabetic and antioxidant effects of Helichrysum graveolens capitulums in streptozotocin-induced diabetic rats. J. Med. Food 10:2 (2007), 396–400.
11. Attele, A.S., et al. Antidiabetic effects of Panax ginseng berry extract and the identification of an effective component. Diabetes 51:6 (2002), 1851–1858.
12. Augusti, K.T., Effect of alloxan diabetes of allyl propyl disulphide obtained from onion. Naturwissenschaften 61:4 (1974), 172–173.
13. Bailey, C.J., Day, C., Traditional plant medicines as treatments for diabetes. Diabetes Care 12:8 (1989), 553–564.
14. Balfour, J.A., McTavish, D., Acarbose. An update of its pharmacology and therapeutic use in diabetes mellitus. Drugs 46:6 (1993), 1025–1054.
15. Beunink, J., Schedel, M., Steiner, U., Osmotically Controlled Fermentation Process for the Preparation of acarbose. 1997 German Patent DE 19637591 (US patent 6, 130, 072).
16. Bowers, S.G., Mahmud, T., Floss, H.G., Biosynthetic studies on the alpha-glucosidase inhibitor acarbose: The chemical synthesis of dTDP-4-amino-4, 6-dideoxy-alpha-D-glucose. Carbohydr. Res. 337:4 (2002), 297–304.
17. Brahmachari, H.D., Augusti, K.T., Isolation of orally effective hypoglycemic compounds from Ficus bengalensis Linn. Indian J. Physiol. Pharmacol. 8 (1964), 60–64.
18. Bressler, R., Corredor, C., Brendel, K., Hypoglycin and hypoglycin-like compounds. Pharmacol. Rev. 21:2 (1969), 105–130.
19. Campbell, L.K., Baker, D.E., Campbell, R.K., Miglitol: Assessment of its role in the treatment of patients with diabetes mellitus. Ann. Pharmacother. 34:11 (2000), 1291–1301.
20. Chase, C.K., McQueen, C.E., Cinnamon in diabetes mellitus. Am. J. Health Syst. Pharm. 64:10 (2007), 1033–1035.
21. Chen, X., Zheng, Y., Shen, Y., Voglibose (Basen, AO-128), one of the most important alpha-glucosidase inhibitors. Curr. Med. Chem. 13:1 (2006), 109–116.
22. Chiasson, J.L., et al. The efficacy of acarbose in the treatment of patients with non-insulin-dependent diabetes mellitus. A multicenter controlled clinical trial. Ann. Intern. Med. 121:12 (1994), 928–935.
23. Chiasson, J.L., et al. Acarbose for prevention of type 2 diabetes mellitus: The STOP-NIDDM randomised trial. Lancet 359:9323 (2002), 2072–2077.
24. Clifford, M.N., Anthocyanins—Nature, occurrence and dietary burden. J. Sci. Food Agric. 80:7 (2000), 1063–1072.
25. Clissold, S.P., Edwards, C., Acarbose. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential. Drugs 35:3 (1988), 214–243.
26. Coniff, R.F., Results of US trials with acarbose in treatment of NIDDM. 1991 FDA application.
27. Coniff, R.F., et al. Multicenter, placebo-controlled trial comparing acarbose (BAY g 5421) with placebo, tolbutamide, and tolbutamide-plus-acarbose in non-insulin-dependent diabetes mellitus. Am. J. Med. 98:5 (1995), 443–451.
28. Cusi, K., DeFronzo, R., Metformin: A review of its metabolic effects. Diabetes Rev. 6:2 (1998), 89–131.
29. de Sousa, E., et al. Hypoglycemic effect and antioxidant potential of kaempferol-3, 7-O-(alpha)-dirhamnoside from Bauhinia forficata leaves. J. Nat. Prod. 67:5 (2004), 829–832.
30. DeFronzo, R.A., Goodman, A.M., Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group. N. Engl. J. Med. 333:9 (1995), 541–549.
31. Deppenmeier, U., Hoffmeister, M., Prust, C., Biochemistry and biotechnological applications of Gluconobacter strains. Appl. Microbiol. Biotechnol. 60:3 (2002), 233–242.
32. Detaille, D., et al. Obligatory role of membrane events in the regulatory effect of metformin on the respiratory chain function. Biochem. Pharmacol. 63:7 (2002), 1259–1272.
33. Dimitriadis, G., et al. Effects of alpha-glucosidase inhibition on meal glucose tolerance and timing of insulin administration in patients with type I diabetes mellitus. Diabetes Care 14:5 (1991), 393–398.
34. Donner, T., Tight control of hyperclycemia in type 2 diabetes mellitus. Insulin 1:4 (2006), 166–172.
35. Du, Z.Y., et al. Alpha-glucosidase inhibition of natural curcuminoids and curcumin analogs. Eur. J. Med. Chem. 41:2 (2006), 213–218.
36. Einhorn, D., et al. Pioglitazone hydrochloride in combination with metformin in the treatment of type 2 diabetes mellitus: A randomized, placebo-controlled study. The Pioglitazone 027 Study Group. Clin. Ther. 22:12 (2000), 1395–1409.
37. Escobar-Jimenez, F., et al. Efficacy and tolerability of miglitol in the treatment of patients with non-insulin-dependent diabetes mellitus. Curr. Ther. Res. 56 (1995), 258–268.
38. Farnsworth, N., Segelman, A., Hypoglycemic plants. Tile Till 57 (1971), 52–55.
39. Fendri, S., et al. Metformin effects on peripheral sensitivity to insulin in non diabetic obese subjects. Diabete Metab. 19:2 (1993), 245–249.
40. Fernandes, N.P., et al. An experimental evaluation of the antidiabetic and antilipidemic properties of a standardized Momordica charantia fruit extract. BMC Complement. Altern. Med., 7, 2007, 29.
41. Folsch, U.R., et al. The enteroinsular axis during treatment with glucosidase inhibitors. Front. Horm. Res. 16 (1987), 197–205.
42. Frommer, W., Puls, W., Schmidt, D., Process for the Production of a Sacchrase Inhibitor. 1977 German Patent DE 2209834 (US patent 4, 019, 960).
43. Frommer, W., et al. Amino Sugar Derivatives. 1977 German Patent DE 2347782 (US patent 4,062,950).
44. Ghannam, N., et al. The antidiabetic activity of aloes: Preliminary clinical and experimental observations. Horm. Res. 24:4 (1986), 288–294.
45. Ghosh, D., Anthocyanins and anthocyanins-rich extracts in biology and medicine: Biochemical, cellular and medicinal properties. Curr. Top. Nutraceutical Res. 3:2 (2005), 113–124.
46. Goke, B., et al. Intestinal effects of alpha-glucosidase inhibitors: Absorption of nutrients and enterohormonal changes. Eur. J. Clin. Invest. 24:Suppl. 3 (1994), 25–30.
47. Goke, B., et al. Voglibose (AO-128) is an efficient alpha-glucosidase inhibitor and mobilizes the endogenous GLP-1 reserve. Digestion 56:6 (1995), 493–501.
48. Goodarzi, M.O., Bryer-Ash, M., Metformin revisited: Re-evaluation of its properties and role in the pharmacopoeia of modern antidiabetic agents. Diabetes Obes. Metab. 7:6 (2005), 654–665.
49. Gray, A.M., Flatt, P.R., Antihyperglycemic actions of Eucalyptus globulus (Eucalyptus) are associated with pancreatic and extra-pancreatic effects in mice. J. Nutr. 128:12 (1998), 2319–2323.
50. Grover, J.K., Yadav, S., Vats, V., Medicinal plants of India with anti-diabetic potential. J. Ethnopharmacol. 81:1 (2002), 81–100.
51. Gunton, J.E., et al. Metformin rapidly increases insulin receptor activation in human liver and signals preferentially through insulin-receptor substrate-2. J. Clin. Endocrinol. Metab. 88:3 (2003), 1323–1332.
52. Hall, R.D., Yeoman, M.M., Temporal and spatial heterogeneity in the accumulation of anthocyanins in cell-cultures of catharanthus-roseus (L) Don, G. J. Exp. Botany 37:174 (1986), 48–60.
53. Hammouda, Y., Amer, M.S., Antidiabetic effect of tecomine and tecostanine. J. Pharm. Sci. 55:12 (1966), 1452–1454.
54. Hammouda, Y., Khalafallah, N., Stability of tecomine, the major antidiabetic factor of Tecoma stans (Juss.) f. bignoniaceae. J. Pharm. Sci. 60:8 (1971), 1142–1145.
55. Hemker, M., et al. Identification, cloning, expression, and characterization of the extracellular acarbose-modifying glycosyltransferase, AcbD, from Actinoplanes sp. strain SE50. J. Bacteriol. 183:15 (2001), 4484–4492.
56. Hermann, M., Herbs and Medicinal Flowers. 1973, Galahad, New York, NY.
57. Hikino, H., et al. Isolation and hypoglycemic activity of ganoderans A and B, glycans of ganoderma lucidum fruit bodies1. Planta Med. 51:4 (1985), 339–340.
58. Hoffmann, J., Spengler, M., Efficacy of 24-week monotherapy with acarbose, glibenclamide, or placebo in NIDDM patients. The Essen study. Diabetes Care 17:6 (1994), 561–566.
59. Hollander, P., Coniff, R.F., Two multicenter, double-blind, placebo-controlled studies of efficacy and safety of acarbose treatment of type I diabetes. Diabetes, 40(Suppl. 1), 1991, 307A.
60. Holman, R.R., et al. Six-years results from early diabetes intervention trail. Diabet. Med., 20(Suppl. 2), 2003, S15 (Abstract).
61. Horii, S., et al. Synthesis and alpha-D-glucosidase inhibitory activity of N-substituted valiolamine derivatives as potential oral antidiabetic agents. J. Med. Chem. 29:6 (1986), 1038–1046.
62. Ibanez-Camacho, R., Meckes-Lozoya, M., Mellado-Campos, V., The hypoglucemic effect of Opuntia streptacantha studied in different animal experimental models. J. Ethnopharmacol. 7:2 (1983), 175–181.
63. Imparl-Radosevich, J., et al. Regulation of PTP-1 and insulin receptor kinase by fractions from cinnamon: Implications for cinnamon regulation of insulin signalling. Horm. Res. 50:3 (1998), 177–182.
64. Jain, R.C., Vyas, C.R., Mahatma, O.P., Letter: Hypoglycaemic action of onion and garlic. Lancet, 2(7844), 1973, 1491.
65. Jayaprakasam, B., et al. Insulin secretion by bioactive anthocyanins and anthocyanidins present in fruits. J. Agric. Food Chem. 53:1 (2005), 28–31.
66. Jimenez, J., et al. Hypoglycemic activity of Salvia lavandulifolia. Planta Med. 52:4 (1986), 260–262.
67. Johnston, P.S., et al. Effects of the carbohydrase inhibitor miglitol in sulfonylurea-treated NIDDM patients. Diabetes Care 17:1 (1994), 20–29.
68. Johnston, P.S., et al. Advantages of alpha-glucosidase inhibition as monotherapy in elderly type 2 diabetic patients. J. Clin. Endocrinol. Metab. 83:5 (1997), 1515–1522.
69. Jones, K., The potential health benefits of purple corn. Herbalgram. Am. Bot. Council 65 (2005), 46–49.
70. Jones, T.A., et al. Addition of rosiglitazone to metformin is most effective in obese, insulin-resistant patients with type 2 diabetes. Diabetes Obes. Metab. 5:3 (2003), 163–170.
71. Karam, J.H., Matin, S.B., Forsham, P.H., Antidiabetic drugs after the University Group Diabetes Program (UGDP). Annu. Rev. Pharmacol. 15 (1975), 351–366.
72. Keppler, K., Humpf, H.U., Metabolism of anthocyanins and their phenolic degradation products by the intestinal microflora. Bioorg. Med. Chem. 13:17 (2005), 5195–5205.
73. Khan, A., et al. Cinnamon improves glucose and lipids of people with type 2 diabetes. Diabetes Care 26:12 (2003), 3215–3218.
74. Kim, M.J., et al. Comparative study of the inhibition of alpha-glucosidase, alpha-amylase, and cyclomaltodextrin glucanosyltransferase by acarbose, isoacarbose, and acarviosine-glucose. Arch. Biochem. Biophys. 371:2 (1999), 277–283.
75. Kim, Y.M., et al. Inhibitory effect of pine extract on alpha-glucosidase activity and postprandial hyperglycemia. Nutrition 21:6 (2005), 756–761.
76. Kinast, G., Schedel, M., Production of N-substituted derivatives of 1-desoxy-nojirimycin. 1979 US patent 4, 266, 025.
77. Konno, C., et al. Isolation and hypoglycemic activity of aconitans A, B, C and D, glycans of Aconitum carmichaeli Roots1. Planta Med. 51:2 (1985), 160–161.
78. Konno, C., Mizuno, T., Hikino, H., Isolation and hypoglycemic activity of ephedrans A, B, C, D and E, glycans of Ephedra distachya Herbs1. Planta Med. 51:2 (1985), 162–163.
79. Krentz, A.J., Bailey, C.J., Oral antidiabetic agents: Current role in type 2 diabetes mellitus. Drugs 65:3 (2005), 385–411.
80. Krentz, A.J., Ferner, R.E., Bailey, C.J., Comparative tolerability profiles of oral antidiabetic agents. Drug Saf. 11:4 (1994), 223–241.
81. Kumar, S., et al. Antidiabetic potential of Phyllanthus reticulatus in alloxan-induced diabetic mice. Fitoterapia 79:1 (2008), 21–23.
82. Kusano, S., Abe, H., Antidiabetic activity of white skinned sweet potato (Ipomoea batatas L.) in obese Zucker fatty rats. Biol. Pharm. Bull. 23:1 (2000), 23–26.
83. Lange, P., Rauenbusch, E., Rauenbusch, Polymers for the Purification of Acarbose. 1986 German Patent DE 3439008 (US patent 4, 767, 850).
84. Lebovitz, H., Oral antidiabetic agents: The emergence of alpha-glucosidase inhibotors. Drugs 44:Suppl. 3 (1992), 21–28.
85. Lebovitz, H., Oral antidiabetic agents: 2004. Med. Clin. North Am. 88 (2004), 847–863.
86. Lelley, J., Investigations on the culture of the ink cap, C. coniurus (Mull ex Fr) Gray. Mushroom J., 129, 1983, 14.
87. Lembcke, B., Folsch, U.R., Creutzfeldt, W., Effect of 1-desoxynojirimycin derivatives on small intestinal disaccharidase activities and on active transport in vitro. Digestion 31:2–3 (1985), 120–127.
88. Leonard, E., et al. Strain improvement of recombinant Escherichia coli for efficient production of plant flavonoids. Mol. Pharm. 5:2 (2008), 257–265.
89. Li, W., et al. Antihyperglycemic effect of Cephalotaxus sinensis leaves and GLUT-4 translocation facilitating activity of its flavonoid constituents. Biol. Pharm. Bull. 30:6 (2007), 1123–1129.
90. Liou, S.S., Liu, I.M., Lai, M.C., The plasma glucose lowering action of Hei-Shug-Pian, the fire-processed product of the root of Aconitum (Aconitum carmichaeli), in streptozotocin-induced diabetic rats. J. Ethnopharmacol. 106:2 (2006), 256–262.
91. Liu, H.W., Thorson, J.S., Pathways and mechanisms in the biogenesis of novel deoxysugars by bacteria. Annu. Rev. Microbiol. 48 (1994), 223–256.
92. Liu, C.J., et al. Bottlenecks for metabolic engineering of isoflavone glycoconjugates in Arabidopsis. Proc. Natl. Acad. Sci. USA 99:22 (2002), 14578–14583.
93. Liu, X., et al. Antidiabetic effect of Pycnogenol French maritime pine bark extract in patients with diabetes type II. Life Sci. 75:21 (2004), 2505–2513.
94. Liu, X., et al. Pycnogenol, French maritime pine bark extract, improves endothelial function of hypertensive patients. Life Sci. 74:7 (2004), 855–862.
95. Lutz, T.A., et al. Depolarization of the liver cell membrane by metformin. Biochim. Biophys. Acta 1513:2 (2001), 176–184.
96. Mahmud, T., The C7N aminocyclitol family of natural products. Nat. Prod. Rep. 20:1 (2003), 137–166.
97. Mahmud, T., et al. Biosynthesis Studies on the alpha-Glucosidase Inhibitor Acarbose in Actinoplanes sp.: 2-epi-5-epi-Valiolone Is the Direct Precursor of the Valienamine Moeity. J. Am. Chem. Soc. 121:30 (1999), 6973–6983.
98. Mai, T.T., et al. Alpha-glucosidase inhibitory and antioxidant activities of Vietnamese edible plants and their relationships with polyphenol contents. J. Nutr. Sci. Vitaminol. (Tokyo) 53:3 (2007), 267–276.
99. Markham, K.R., Porter, L.J., Extractives of Pinus radiata bark 1, phenolic compounts. N. Z. J. Sci. 56 (1973), 751–761.
100. Maroo, J., et al. Glucose lowering effect of aqueous extract of Enicostemma littorale Blume in diabetes: A possible mechanism of action. J. Ethnopharmacol. 81:3 (2002), 317–320.
101. Matsui, T., et al. alpha-Glucosidase inhibitory action of natural acylated anthocyanins. 2. alpha-Glucosidase inhibition by isolated acylated anthocyanins. J. Agric. Food Chem. 49:4 (2001), 1952–1956.
102. Matsui, T., et al. alpha-Glucosidase inhibitory action of natural acylated anthocyanins. 1. Survey of natural pigments with potent inhibitory activity. J. Agric. Food Chem. 49:4 (2001), 1948–1951.
103. Matsui, T., et al. Caffeoylsophorose, a new natural alpha-glucosidase inhibitor, from red vinegar by fermented purple-fleshed sweet potato. Biosci. Biotechnol. Biochem. 68:11 (2004), 2239–2246.
104. Matsuo, T., Odaka, H., Ikeda, H., Effect of an intestinal disaccharidase inhibitor (AO-128) on obesity and diabetes. Am. J. Clin. Nutr. 55:1 Suppl (1992), 314S–317S.
105. McDougall, G.J., Stewart, D., The inhibitory effects of berry polyphenols on digestive enzymes. Biofactors 23:4 (2005), 189–195.
106. McDougall, G.J., et al. Different polyphenolic components of soft fruits inhibit alpha-amylase and alpha-glucosidase. J. Agric. Food Chem. 53:7 (2005), 2760–2766.
107. McIntyre, H.D., et al. Metformin increases insulin sensitivity and basal glucose clearance in type 2 (non-insulin dependent) diabetes mellitus. Aust. N. Z. J. Med. 21:5 (1991), 714–719.
108. Meyer, J.E., Pepin, M.F., Smith, M.A.L., Anthocyanin production from Vaccinium pahalae: Limitations of the physical micro environment. J. Biotechnol. 93:1 (2002), 45–57.
109. Mishkinsky, J.S., et al. Hypoglycaemic effect of Trigonella foenum graecum and Lupinus termis (leguminosae) seeds and their major alkaloids in alloxan-diabetic and normal rats. Arch. Int. Pharmacodyn. Ther. 210:1 (1974), 27–37.
110. Nelson-Dooley, C., et al. Novel treatments for obesity and osteoporosis: Targeting apoptotic pathways in adipocytes. Curr. Med. Chem. 12:19 (2005), 2215–2225.
111. Ojewole, J.A., Evaluation of the analgesic, anti-inflammatory and anti-diabetic properties of Sclerocarya birrea (A. Rich.) Hochst. stem-bark aqueous extract in mice and rats. Phytother. Res. 18:8 (2004), 601–608.
112. Okyar, A., et al. Effect of Aloe vera leaves on blood glucose level in type I and type II diabetic rat models. Phytother Res. 15:2 (2001), 157–161.
113. Olaniyi, A.A., A neutral constituent of Momordica foetida. Lloydia 38:4 (1975), 361–362.
114. Pagano, G., et al. Comparison of miglitol and glibenclamide in diet-treated type 2 diabetic patients. Diabete Metab. 21:3 (1995), 162–167.
115. Peters, G., Ubersichten Insulin: Ersatzmittel Pflanzlichen Ursprungs (Review of insulin substitutes from vegetable resources). Dtsch. Med. Wochenschr. 82 (1957), 320–322.
116. Piepersberg, W., Pathway engineering in secondary metabolite-producing actinomycetes. Crit. Rev. Biotechnol. 14:3 (1994), 251–285.
117. Piepersberg, W., Molecular biology, biochemistry and fermentation of aminoglycoside antibiotics. Biotechnol. Ind. Antibiot., 1997, 81–163.
118. Piepersberg, W., Distler, J., Aminoglycosides and sugar components in other secondary metabolites. Rehm, H.-J., Reed, G., Puhler, A., Stadler, P., (eds.) Biotechnology Products of secondary metabolism, Vol. 7, 1997, 397–488.
119. Piepersberg, W., et al. Recent Develoments in the biosynthesis and regulation of aminoglycosides. Fierro, F., Martin, J.F., (eds.) Microbial Secondary Metabolites: Biosynthesis, Genetics and Regulation, 2002, 1–26.
120. Prior, R.L., Wu, X., Anthocyanins: Structural characteristics that result in unique metabolic patterns and biological activities. Free Radic. Res. 40:10 (2006), 1014–1028.
121. Putter, J., et al. Pharmacokinetics of Acarbose. Proceedings of First International Synopsium on Acarbose, 1982, 38–48.
122. Quesada, C., et al. Phenolic inhibitors of α-amylase and trypsin enzymes by extracts from pears, lentils, and cocoa. J. Food Prot. 59:2 (1996), 185–192.
123. Rauenbusch, E., Highly Pure Acarbose. 1987 German Patent DE 3543999 (US patent 4, 904, 769).
124. Rauenbusch, E., Schmidt, D., Process for Isolating Glucopyranose Compound from Culture Broths. 1978 German Patent DE 2719912 (US patent 4, 174, 439).
125. Sanbongi, C., Suzuki, N., Sakane, T., Polyphenols in chocolate, which have antioxidant activity, modulate immune functions in humans in vitro. Cell. Immunol. 177:2 (1997), 129–136.
126. Schafer, A., Hogger, P., Oligomeric procyanidins of French maritime pine bark extract (Pycnogenol) effectively inhibit alpha-glucosidase. Diabetes Res. Clin. Pract. 77:1 (2007), 41–46.
127. Schedel, M., Regioselective oxidation of aminosorbitol with Glucanobactor oxydans, a key reaction in the industrial synthesis of 1-deoxynojirimycin. Kelly, D.R., (eds.) Biotechnology Biotransformations II, Vol. 8b, 2000, 296–308.
128. Scheen, A.J., Is there a role for alpha-glucosidase inhibitors in the prevention of type 2 diabetes mellitus?. Drugs 63:10 (2003), 933–951.
129. Scheen, A.J., Antidiabetic agents in subjects with mild dysglycaemia: Prevention or early treatment of type 2 diabetes?. Diabetes Metab. 33:1 (2007), 3–12.
130. Scheen, A.J., et al. Reduction of metformin acute bioavailability by the alpha-glucosidase inhibitor acarbose in normal man. Eur. J. Clin. Invest., 23(Suppl. 1), 1993.
131. Scheen, A.J., et al. Reduction of the acute bioavailability of metformin by the alpha-glucosidase inhibitor acarbose in normal man. Eur. J. Clin. Invest. 3:Suppl (1994), 50–54.
132. Schmidt, D.D., et al. Glucosidase inhibitors from Bacilli. Naturwissenschaften 66:11 (1979), 584–585.
133. Scott, L.J., Spencer, C.M., Miglitol: A review of its therapeutic potential in type 2 diabetes mellitus. Drugs 59:3 (2000), 521–549.
134. Sharaf, A.A., Hussein, A.M., Mansour, M.Y., The anti-diabetic effect of some plants. Planta Med. 11 (1963), 159–168.
135. Shibib, B.A., Khan, L.A., Rahman, R., Hypoglycaemic activity of Coccinia indica and Momordica charantia in diabetic rats: Depression of the hepatic gluconeogenic enzymes glucose-6-phosphatase and fructose-1, 6-bisphosphatase and elevation of both liver and red-cell shunt enzyme glucose-6-phosphate dehydrogenase. Biochem. J. 292:Pt 1 (1993), 267–270.
136. Smith, M.A.L., Spomer, L.A., Vessels, gels, liquid media, and support systems. Aitken-Christie, J., Kozai, T., Smith, M.A.L., (eds.) Automation and Environmental Control in Plant Tissue Culture, 1995, Kluwer Academic Publishers, Dordrecht, The Netherlands, 371–404.
137. Stanely, P., Prince, M., Menon, V.P., Hypoglycaemic and other related actions of Tinospora cordifolia roots in alloxan-induced diabetic rats. J. Ethnopharmacol. 70:1 (2000), 9–15.
138. Suda, I., et al. Physiological functionality of purple-fleshed sweet potatoes containing anthocyanins and their utilization in foods. JARQ 37:3 (2003), 167–173.
139. Swanston-Flatt, S.K., et al. Glycaemic effects of traditional European plant treatments for diabetes. Studies in normal and streptozotocin diabetic mice. Diabetes Res. 10:2 (1989), 69–73.
140. Swanston-Flatt, S.K., et al. Traditional plant treatments for diabetes. Studies in normal and streptozotocin diabetic mice. Diabetologia 33:8 (1990), 462–464.
141. Syiem, D., et al. Hypoglycemic effects of Potentilla fulgens L. in normal and alloxan-induced diabetic mice. J. Ethnopharmacol. 83:1–2 (2002), 55–61.
142. Takahashi, M., Konno, C., Hikino, H., Isolation and hypoglycemic activity of saccharans A, B, C, D, E and F, glycans of Saccharum officinarum Stalks1. Planta Med. 51:3 (1985), 258–260.
143. Tan, M., Alpha-glucosidase inhibitors in the treatment of diabetes. Curr. Opin. Endocrinol. Diabetes 4:1 (1997), 48–55.
144. Tatusov, R.L., et al. The COG database: New developments in phylogenetic classification of proteins from complete genomes. Nucleic Acids Res. 29:1 (2001), 22–28.
145. Terahara, N., et al. Five new anthocyanins, ternatins A3, B4, B3, B2, and D2, from Clitoria ternatea flowers. J. Nat. Prod. 59:2 (1996), 139–144.
146. Terahara, N., et al. Six diacylated anthocyanins from purple sweet potato, Ipomoea batatas cv Yamagawamurasaki. Biosci. Biotechnol. Biochem. 63 (1999), 1420–1424.
147. Thomas, H., Acarbose Metabolismus in Actinplanes sp. query, 2001.
148. Toeller, M., alpha-Glucosidase inhibitors in diabetes: Efficacy in NIDDM subjects. Eur. J. Clin. Invest. 24:Suppl. 3 (1994), 31–35.
149. Torres, I.C., Suarez, J.C., A preliminary study of hypoglycemic activity of Lythrum salicaria. J. Nat. Prod. 43:5 (1980), 559–563.
150. U.K. prospective diabetes study 16. Overview of 6 years' therapy of type II diabetes: A progressive disease. U.K. Prospective Diabetes Study Group. Diabetes 44:11 (1995), 1249–1258.
151. Verspohl, E.J., Bauer, K., Neddermann, E., Antidiabetic effect of Cinnamomum cassia and Cinnamomum zeylanicum in vivo and in vitro. Phytother. Res. 19:3 (2005), 203–206.
152. Vichayanrat, A., et al. Efficacy and safety of voglibose in comparison with acarbose in type 2 diabetic patients. Diabetes Res. Clin. Pract. 55:2 (2002), 99–103.
153. Vijayakumar, M.V., et al. The hypoglycaemic activity of fenugreek seed extract is mediated through the stimulation of an insulin signalling pathway. Br. J. Pharmacol. 146:1 (2005), 41–48.
154. Wagman, A.S., Nuss, J.M., Current therapies and emerging targets for the treatment of diabetes. Curr. Pharm. Des. 7:6 (2001), 417–450.
155. Wang, H.J., Murphy, P.A., Mass balance study of isoflavones during soybean processing. J. Agric. Food Chem. 44:8 (1996), 2377–2383.
156. Watanabe, C.K., Studies in the metabolic changes induced by administration of guanidine bases. I. Influence of injected guanidine hydrochloride upon blood sugar content. J. Biol. Chem. 33 (1918), 253–265.
157. Wehmeier, U.F., The biosynthesis and metabolism of acarbose in Actinoplanes sp. SE50/110: A progress report. Biocatal. Biotransformation 21 (2003), 279–284.
158. Wehmeier, U.F., Piepersberg, W., Biotechnology and molecular biology of the alpha-glucosidase inhibitor acarbose. Appl. Microbiol. Biotechnol. 63:6 (2004), 613–625.
159. Wellmann, E., UV dose-dependent induction of enzymes related to flavonoid biosynthesis in cell-suspension cultures of parsley. FEBS Lett. 51:1 (1975), 105–107.
160. Witters, L.A., The blooming of the French lilac. J. Clin. Invest. 108:8 (2001), 1105–1107.
161. Wu, X., Prior, R.L., Identification and characterization of anthocyanins by high-performance liquid chromatography-electrospray ionization-tandem mass spectrometry in common foods in the United States: Vegetables, nuts, and grains. J. Agric. Food Chem. 53:8 (2005), 3101–3113.
162. Wu, X., et al. Aglycones and sugar moieties alter anthocyanin absorption and metabolism after berry consumption in weanling pigs. J. Nutr. 135:10 (2005), 2417–2424.
163. Xie, J.T., McHendale, S., Yuan, C.S., Ginseng and diabetes. Am. J. Chin. Med. 33:3 (2005), 397–404.
164. Yan, Y., et al. Metabolic engineering of anthocyanin biosynthesis in Escherichia coli. Appl. Environ. Microbiol. 71:7 (2005), 3617–3623.
165. Yan, Y.J., Li, Z., Koffas, M.A.G., High-yield anthocyanin biosynthesis in engineered Escherichia coli. Biotechnol. Bioeng. 100:1 (2008), 126–140.
166. Yang, W., Lin, L., Qi, J., The preventing effect of acarbose and metformin on the IGT population from becoming diabetes mellitus: A 3 year multicentre prospective study. Chin. J. Endocrinol. Metab. 17 (2001), 131–136.
167. Youn, J.Y., Park, H.Y., Cho, K.H., Anti-hyperglycemic activity of Commelina communis L.: Inhibition of alpha-glucosidase. Diabetes Res. Clin. Pract. 66:Suppl. 1 (2004), S149–S155.
168. Yu, O., et al. Metabolic engineering to increase isoflavone biosynthesis in soybean seed. Phytochemistry 63:7 (2003), 753–763.
169. Zhang, C.S., et al. Biosynthesis of the C(7)-cyclitol moiety of acarbose in Actinoplanes species SE50/110. 7-O-phosphorylation of the initial cyclitol precursor leads to proposal of a new biosynthetic pathway. J. Biol. Chem. 277:25 (2002), 22853–22862.
170. Zhang, C.S., et al. The acarbose-biosynthetic enzyme AcbO from Actinoplanes sp. SE 50/110 is a 2-epi-5-epi-valiolone-7-phosphate 2-epimerase. FEBS Lett. 540:1–3 (2003), 47–52.
171. Zhang, C.S., et al. Identification of a 1-epi-valienol 7-kinase activity in the producer of acarbose, Actinoplanes sp. SE50/110. FEBS Lett. 540:1–3 (2003), 53–57.
172. Zhu, G., et al. Analysis and bio activity detection of the α-glucosidase inhibitors in total alkaloids from Feculae bombycis. Chin. Tradit. Herbal Drugs 36 (2005), 159–162.